RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cantabio Pharmaceuticals Stock

Cantabio Pharmaceuticals ROCE 2024

Cantabio Pharmaceuticals ROCE

0

Ticker

CTBO

ISIN

US13808X2036

WKN

A2PMPJ

In 2024, Cantabio Pharmaceuticals's return on capital employed (ROCE) was 0, a 0% increase from the 0 ROCE in the previous year.

Cantabio Pharmaceuticals Aktienanalyse

What does Cantabio Pharmaceuticals do?

Cantabio Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in the development of innovative therapies for neurodegenerative diseases. The company was founded in 2009 by Professor Gou-Ping Chen, an expert in protein structures and functions. Cantabio Pharmaceuticals was established specifically to address neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's, which are among the largest and most prevalent diseases in the aging population. The business model of Cantabio Pharmaceuticals is based on the development of products that have been developed based on new insights in molecular research and increased understanding of neurodegenerative diseases. By collaborating with universities, research laboratories, and other industry partners, the company employs an innovation strategy to present novel solutions to the public. For its research and products, the company focuses on three main areas: - Drug discovery - the company has a variety of products in the pipeline, from discovery to clinical phases, which are strictly regulated by the FDA. - Protein and antibody manufacturing - the company uses the latest technologies to manipulate proteins to maximize their beneficial effects and optimize their potential therapeutic efficacy. - Diagnostic tools - the company also develops diagnostic tests and analysis tools for the detection of biomarkers to enable faster and more accurate diagnosis. In basic research, the company has discovered a novel class of proteins called Alpha-Synuclein inhibitors. Alpha-Synuclein is a protein that is associated with Parkinson's disease due to its overproduction and accumulation. Through experiments, Cantabio scientists have discovered substances to inhibit or even reduce its production and accumulation. These discoveries have gained significant attention in the scientific community and could contribute to important advances in understanding and overcoming brain pathologies. Cantabio Pharmaceuticals' products include a range of treatments applicable to specific diseases. One of the company's most important products is the novel drug CB2813, which targets the treatment of Alzheimer's and other neurodegenerative diseases. CB2813 represents an innovation in the treatment of Alzheimer's by combating the progression of the disease at the molecular level and strengthening the brain's biochemical protection. Another product of Cantabio Pharmaceuticals is the Alpha-Synuclein inhibitor CNS5874, which is used in Parkinson's disease. Parkinson's disease is characterized by the loss of dopamine receptors and the accumulation of Alpha-Synuclein protein. Administration of CNS5874 can reduce the accumulated Alpha-Synuclein protein in the brain regions significantly affected by the disease and promote improvement in patient behavior. Overall, Cantabio Pharmaceuticals is a leading company in the field of neurodegenerative diseases, focusing on the development of innovative treatment methods. In order to expand its pipeline and improve the available treatment options for patients, the company is constantly developing new products, some of which are already in research and clinical development. Cantabio Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Cantabio Pharmaceuticals's Return on Capital Employed (ROCE)

Cantabio Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Cantabio Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Cantabio Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Cantabio Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Cantabio Pharmaceuticals stock

What is the ROCE (Return on Capital Employed) of Cantabio Pharmaceuticals this year?

The ROCE of Cantabio Pharmaceuticals is 0 undefined this year.

How has the ROCE (Return on Capital Employed) of Cantabio Pharmaceuticals developed compared to the previous year?

The ROCE of Cantabio Pharmaceuticals has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Cantabio Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Cantabio Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Cantabio Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Cantabio Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Cantabio Pharmaceuticals impact the company?

An increase in the ROCE of Cantabio Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Cantabio Pharmaceuticals affect the company?

A decrease in ROCE of Cantabio Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Cantabio Pharmaceuticals?

Some factors that can affect Cantabio Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Cantabio Pharmaceuticals so important for investors?

The ROCE of Cantabio Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Cantabio Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Cantabio Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Cantabio Pharmaceuticals pay?

Over the past 12 months, Cantabio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cantabio Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Cantabio Pharmaceuticals?

The current dividend yield of Cantabio Pharmaceuticals is .

When does Cantabio Pharmaceuticals pay dividends?

Cantabio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cantabio Pharmaceuticals?

Cantabio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Cantabio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cantabio Pharmaceuticals located?

Cantabio Pharmaceuticals is assigned to the '-' sector.

Wann musste ich die Aktien von Cantabio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cantabio Pharmaceuticals from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Cantabio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Cantabio Pharmaceuticals in the year 2023?

In the year 2023, Cantabio Pharmaceuticals distributed 0 USD as dividends.

In which currency does Cantabio Pharmaceuticals pay out the dividend?

The dividends of Cantabio Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cantabio Pharmaceuticals

Our stock analysis for Cantabio Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cantabio Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.